Quelling the COVID-19 Cytokine Storm in Hospitalized Patients: Current Thinking, Emerging Data
Release Date: December 17, 2021
Expiration Date: December 17, 2022
Time to Complete Activity: 1.0 hour
Leonard Calabrese, DO
Professor of Medicine
Director, RJ Fasenmyer Centre for Clinical Immunology
Vice Chair, Department of Rheumatic and Immunologic Disease
Co-Director, Centre for Vasculitis Care and Research
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Leslie Tolle, MD
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Interim Director, Section of Diffuse Parenchymal Lung Disease
Respiratory Institute, Cleveland Clinic
This activity is provided by Paradigm Medical Communications, LLC.
Disclosure of Financial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
This activity has been designed for a range of clinicians who are integral in managing patients with severe COVID-19 throughout hospitalization (critical care specialists, infectious disease specialists, emergency medicine physicians, pulmonologists, hospitalists, and primary care clinicians). The activity may be of benefit to other clinicians involved in the treatment of hospitalized patients with severe COVID-19 who often have little experience with immunomodulatory treatment.
Statement of Need
The search for optimal COVID-19 treatment remains an urgent priority, especially in hospitalized patients who are at the highest risk for mortality and other negative outcomes. An appreciation of the “cytokine storm” in severe COVID-19 has illuminated a role for interleukin-6 (IL-6) inhibition using tocilizumab, an IL-6 receptor blocker, or Janus kinase (JAK) inhibition in certain patients. Continually emerging data, evolving guideline recommendations, and confusion about patient selection and the optimal timing of treatment initiation challenge hospital-based clinicians to keep pace and make appropriate, evidence-based care decisions. This webinar reviews current thinking on the role of recommended immunomodulatory therapies and agents in late-phase investigation, including the pathophysiological processes they target, contextualization of clinical trial data discussed and illustrated in whiteboard animations, and with expert-led discussion to help clinicians make individualized COVID treatment decisions in the hospital.
Upon completion of this activity, participants should be able to:
- Identify key characteristics of COVID-19 pathophysiology that are associated with more progressive and severe disease
- Summarize efficacy and safety of treatments that are recommended to treat hospitalized patients with severe COVID-19
- Make immunomodulatory treatment decisions (eg, agent selection and timing of initiation) for hospitalized patients with severe COVID-19 based on clinical characteristics and current data
- COVID Acute Respiratory Distress Syndrome (ARDS) Case
- A “Rheum” With a View: The Cytokine Storm in Severe COVID-19
- Whiteboard: Pathophysiology of the Immune Response to COVID Infection
- Whiteboard: Development and Management of the Hyperimmune Response to COVID Infection
- Whiteboard: Current Treatment of Hospitalized Patients With COVID Infection
- COVID ARDS Treatment
- COVID ARDS Case (Resumed)
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or email@example.com.
There is no fee required for participation in this activity.
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at firstname.lastname@example.org.
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any financial relationships occurring over the past 24 months with ineligible companies whose products or services are associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been mitigated.
Leonard Calabrese, DO
Consultant: Genentech, Inc.; GlaxoSmithKline
Leslie B. Tolle, MD
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc. (expired 12/20)
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are mitigated through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not ap
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at email@example.com.
© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.